HanAll Biopharma announced the appointment of Christopher W. Slavinsky as Chief Business Development and Legal Officer. Chris is expected to leverage his extensive background as a strategic and operationally focused leader with over 25 years of expertise in legal and business development roles within large pharmaceutical companies and small, emerging biotechnology firms. Spanning annual revenues from $50 million to $50 billion, he has overseen more than $20 billion in strategic transactions, including transformative M&A, integration efforts, asset acquisitions, and divestitures aimed at driving growth, ensuring regulatory compliance, and optimizing the company's market position across R&D, commercial operations, and investor relations functions. Chris joins HanAll from Coherus BioSciences, where he served as Chief Business and Legal Officer and led its $65M all-stock acquisition of Surface Oncology and a groundbreaking biosimilars partnership with Cost Plus Drugs.

Previously, Chris held leadership positions at Pharmacosmos Therapeutics, Prometheus Biosciences, Takeda, and Pfizer. Chris holds a JD from Washington University in St. Louis, an MS in Biochemistry and Molecular Biology from Thomas Jefferson University and a BS in Biochemistry from the State University of New York at Stony Brook.